DelveInsight’s, “Oropharyngeal Cancer Pipeline Insight, 2023,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Oropharyngeal Cancer pipeline landscape. It covers the Oropharyngeal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

For Oropharyngeal Cancer Emerging drugs, the Oropharyngeal Cancer pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Oropharyngeal Cancer pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

In the Oropharyngeal Cancer Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Oropharyngeal Cancer clinical trials studies, Oropharyngeal Cancer NDA approvals (if any), and product development activities comprising the technology, Oropharyngeal Cancer collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Key takeaways from the Oropharyngeal Cancer Pipeline Report

 

• DelveInsight’s Oropharyngeal Cancer Pipeline analysis depicts a robust space with 10+ active players working to develop 10+ pipeline treatment therapies.

 

• The leading Oropharyngeal Cancer Companies includes AstraZeneca, ISA Pharmaceuticals, Pfizer, Bristol Myers Squibb, Advaxis, PDS Biotechnology, Debiopharm, Merck KGaA, Regeneron Pharmaceuticals/Sanofi, and others

 

• Promising Oropharyngeal Cancer Pipeline Therapies includes ISA101b, Cemiplimab, Transoral robotic surgery, Nivolumab Injection, Radiotherapy (RT), GC4419, ADXS11-001 (ADXS-HPV), Nivolumab, Carboplatin, Paclitaxel, Radiation Therapy, NBTXR3 activated by IMRT, Durvalumab, TBio-6517, and others.

 

• The Oropharyngeal Cancer companies and academics are working to assess challenges and seek opportunities that could influence Oropharyngeal cancer R&D. The Oropharyngeal Cancer pipeline therapies under development are focused on novel approaches to treat/improve Oropharyngeal Cancer.

 

Request a sample and discover the recent breakthroughs happening in the Oropharyngeal Cancer Pipeline landscape @ Oropharyngeal Cancer Pipeline Outlook Report

 

Oropharyngeal Cancer Overview

Oropharyngeal Cancer is cancer in the oropharynx, which is the middle part of your throat (pharynx). The oropharynx includes the back one-third of the tongue, tonsils, soft palate and the side and back walls of the throat. Oropharyngeal Cancer is a type of head and neck cancer that accounts for about 18,000 newly diagnosed cases in the U.S. every year. Most oropharyngeal cancers are squamous cell carcinomas, meaning that the cancer is affecting your squamous cells, which are thin flat cells found in the lining of most of your organs.

 

Oropharyngeal Cancer Emerging Drugs Profile

 

• Cisplatin: AstraZeneca

Cisplatin works by stopping the cancer cells from multiplying. It does this by binding together the strands of the cells’ genetic material, DNA. Cisplatin binds to the N7 reactive center on purine residues and as such can cause deoxyribonucleic acid (DNA) damage in cancer cells, blocking cell division and resulting in apoptotic cell death. The drug is being evaluated in Phase III clinical trials in combination with Durvalumab for the treatment of patients with Oropharyngeal cancer.

 

• ISA101B: ISA Pharmaceuticals

ISA101 consists of 12 synthetic long peptides (25 to 35 amino acids long) derived from the E6 and E7 oncogenic proteins of the HPV 16 virus, a strain responsible for over 50% of human cervical cancers and cervical intra-epithelial neoplasias, more than 85% of HPV-positive head and neck cancers, and similar substantial percentages of other premalignant and malignant HPV-induced lesions (such as VIN, vulvar cancer, AIN and anal cancer). It is currently administered either subcutaneously or intradermally. The drug is currently in Phase II stage of development for the treatment of patients with Oropharyngeal cancer.

 

Request a sample and discover the recent breakthroughs happening in the Oropharyngeal Cancer Pipeline landscape @ Oropharyngeal Cancer Pipeline Outlook Report

 

Oropharyngeal Cancer Pipeline Therapeutics Assessment

There are approx. 10+ key companies which are developing the therapies for Oropharyngeal Cancer. The companies which have their Oropharyngeal Cancer drug candidates in the most advanced stage, i.e. Phase III include, AstraZeneca.

 

Oropharyngeal Cancer Pipeline

Phases

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

 

Find out more about the Oropharyngeal Cancer Pipeline Segmentation, Therapeutics Assessment, and Oropharyngeal Cancer Emerging Drugs @ Oropharyngeal Cancer Treatment Landscape

 

Scope of the Oropharyngeal Cancer Pipeline Report

 

• Coverage- Global

 

• Oropharyngeal Cancer Companies- AstraZeneca, ISA Pharmaceuticals, Pfizer, Bristol Myers Squibb, Advaxis, PDS Biotechnology, Debiopharm, Merck KGaA, Regeneron Pharmaceuticals/Sanofi, and others

 

• Oropharyngeal Cancer Pipeline Therapies includes ISA101b, Cemiplimab, Transoral robotic surgery, Nivolumab Injection, Radiotherapy (RT), GC4419, ADXS11-001 (ADXS-HPV), Nivolumab, Carboplatin, Paclitaxel, Radiation Therapy, NBTXR3 activated by IMRT, Durvalumab, TBio-6517, and others.

 

• Oropharyngeal Cancer Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

 

Got Queries? Find out the related information on Oropharyngeal Cancer Mergers and acquisitions, Oropharyngeal Cancer Licensing Activities @ Oropharyngeal Cancer Recent Trends, and Future Perspectives

 

Table of Content

1. Introduction
2. Executive Summary
3. Oropharyngeal Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Oropharyngeal Cancer – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Oropharyngeal Cancer Collaboration Deals
9. Late Stage Products (Phase III)
10. Cisplatin: AstraZeneca
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. ISA101B: ISA Pharmaceuticals
14. Drug profiles in the detailed report…..
15. Early stage products (Phase I/II)
16. Genakumab: GeneScience Pharmaceuticals
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Oropharyngeal Cancer Key Companies
20. Oropharyngeal Cancer Key Products
21. Oropharyngeal Cancer- Unmet Needs
22. Oropharyngeal Cancer- Market Drivers and Barriers
23. Oropharyngeal Cancer- Future Perspectives and Conclusion
24. Oropharyngeal Cancer Analyst Views
25. Oropharyngeal Cancer Key Companies
26. Appendix

 

Got Queries? Find out the related information on Oropharyngeal Cancer Mergers and acquisitions, Oropharyngeal Cancer Licensing Activities @ Oropharyngeal Cancer Recent Trends, and Future Perspectives

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/